Compare Abeona Therapeutics Inc (ABEO) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Materials Select Sector SPDR Fund — how do they compare? Abeona Therapeutics Inc trades at $7.41 (market cap $421.19M), while Materials Select Sector SPDR Fund trades at $52.66. Which is the better fit depends on your goals.
| ABEO | XLB | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | — |
52-Week High | $7.45 | $53.62 |
52-Week Low | $4.17 | $42.23 |
Enterprise Value | $276.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
XLB (Materials Select Sector SPDR ETF) trades at $52.68, down 0.94% on the day, while maintaining a bullish technical outlook with strong moving average support. The materials sector benefits from infrastructure spending and AI-related demand, though recent price action suggests some consolidation after the sector rebound. Technical indicators show mixed signals with overbought short-term RSI but strong trend momentum.
The ETF offers diversified exposure to materials companies with cyclical recovery potential, though valuation metrics appear limited after recent gains. Key risks include economic sensitivity and commodity price volatility, while positive earnings momentum and institutional interest provide support for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
